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Abstract
Background: A patent ductus arteriosus (PDA) is frequently found in very preterm neonates and is associated with
increased risk of morbidity and mortality. A shunt across a PDA can result in an unfavorable distribution of the cardiac
output and may in turn result in poor renal perfusion. Urinary Neutrophil Gelatinase-associated Lipocalin (U-NGAL) is a
marker of renal ischemia and may add to the evaluation of PDA. Our primary aim was to investigate if
U-NGAL is associated with PDA in very preterm neonates. Secondary, to investigate whether U-NGAL and
PDA are associated with AKI and renal dysfunction evaluated by fractional excretion of sodium (FENa) and
urine albumin in a cohort of very preterm neonates.
Methods: A cohort of 146 neonates born at a gestational age less than 32 weeks were consecutively examined with
echocardiography for PDA and serum sodium, and urine albumin and sodium were measured on postnatal day 3 and
U-NGAL and serum creatinine day 3 and 6. AKI was defined according to modified neonatal Acute Kidney
Injury Network (AKIN) criteria. The association between U-NGAL and PDA was investigated. And secondly we
investigated if PDA and U-NGAL was associated with AKI and renal dysfunction.
Results: U-NGAL was not associated with a PDA day 3 when adjusted for gestational age and gender. A PDA
day 3 was not associated with AKI when adjusted for gestational age and gender; however, it was associated
with urine albumin. U-NGAL was not associated with AKI, but was found to be associated with urine albumin
and FENa.
Conclusions: Based on our study U-NGAL is not considered useful as a diagnostic marker to identify very preterm
neonates with a PDA causing hemodynamic changes resulting in early renal morbidity. The interpretation of NGAL in
preterm neonates remains to be fully elucidated.
Keywords: Acute kidney injury, Neutrophil gelatinase-associated lipocalin, Patent ductus arteriosus, Very preterm
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Background
A patent ductus arteriosus (PDA) in preterm neonates is
associated with an increased risk of morbidity and mor-
tality [1, 2]. On day 3 of life, up to 50% of neonates born
before 32 weeks of gestation have a PDA [1, 3]. How-
ever, not every PDA challenges the preterm neonate. We
have previously demonstrated that a PDA diameter
above 1.5 mm on postnatal day 3 can be used to identify
a clinically significant PDA [1]. However, further diag-
nostic tools are needed in order to understand the po-
tential impact of PDA presence and optimize handling
of PDA in very preterm neonates.
Neutrophil gelatinase-associated lipocalin (NGAL) is
expressed in low concentrations in many organs and the
expression is up-regulated during infection, inflamma-
tion, and ischemia [4, 5]. Furthermore, NGAL is believed
to be involved in renal development [6]. Urinary NGAL
is produced in the renal tubule of the thick ascending
limb of Henle and the collecting ducts [7]. In preterm
neonates, NGAL has been suggested to be associated
with Acute Kidney Injury (AKI) [8, 9].
U-NGAL has been hypothesized to be increased in the
presence of a PDA [10]. A shunt across a PDA may
result in an unfavorable distribution of the cardiac out-
put between the pulmonary and the systemic circulation.
This may in turn result in poor renal perfusion. This
could cause AKI or renal dysfunction due to ischemia
which could increase U-NGAL [11].
The aim of this study was to evaluate if U-NGAL can
be used as a diagnostic marker to identity very preterm
neonates with a PDA causing hemodynamic changes
resulting in renal morbidity within the first week of life.
To do this we investigated if U-NGAL is associated with
PDA in very preterm neonates. Secondly we investigated
whether U-NGAL and PDA were associated with AKI
and renal dysfunction evaluated by fractional excretion




The study population has previously been described [1],
in brief, newborns born at gestational age below 32 weeks
admitted to Aarhus University Hospital were eligible.
We excluded neonates with chromosomal abnormalities
or congenital heart malformations other than atrial
septum defects from the study (Fig. 1).
Data collection and definitions
Irrespective of clinical symptoms, all very preterm neo-
nates had an echocardiography on day 3 (equal to 72 h).
Urine samples and blood samples were collected day 3
and 6. Urine was collected with a cotton ball placed at
the perineum [8, 9, 12]. The diaper was checked at least
every 4 h and the cotton transferred to a refrigerator.
Cotton was centrifuged at 1000 rpm for 1 min and the
urine was stored at −80 °C within 24 h after collection.
From the patient medical records we collected the
following clinical details: gestational age at birth (deter-
mined by ultrasound), birth weight, multiple births,
Apgar score, early onset sepsis (defined as seven days of
antibiotics initiated within the first 3 days after birth)
[13, 14], surfactant administration, packed red blood cell
transfusion (within the first 3 days), use of inotropes
(within the first 3 days), maternal preeclampsia, ante-
natal steroid administration, and mode of delivery.
Clinical guidelines
Management of the PDA was in accordance with in-
stitutional clinical guideline. Treatment with Ibupro-
fen (Pedea, Orphan Europe SARL Puteaux, France)
was initiated based on detection by echocardiography
alone if the gestational age at birth was less than
28 weeks; otherwise treatment was initiated based on
a combination of specific echocardiographic findings
and clinical symptoms. Ibuprofen was never adminis-
tered before day 3.
Fig. 1 Study population from 184 very preterm neonates admitted
to Aarhus University Hospital (AUH)
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Echocardiographic measurements
A complete diagnostic echocardiography was performed
by two senior pediatric echocardiographers (J Bjerre and
MR Schmidt) by use of standard neonatal windows. A
Philips IE33 Ultrasound machine with a 12-MHz cardi-
ology probe (Philips Healthcare, Andover, Massachusetts,
USA) was used. A PDA was defined as present if flow
could be visualized on colour Doppler. The PDA diameter
was measured in two-dimensional mode at the most
narrow point. A mean value of three cardiac cycles was
calculated. A large PDA was defined as a PDA with a
diameter of 1.5 mm or more and a small PDA as a PDA
with a diameter below 1.5 mm.
U-NGAL measurement
The U-NGAL test Reagent Kit from BioPorto was used
(BioPorto, Copenhagen, Denmark) as routine analysis
on the Cobas 6000 analyzer system (Roche, Basel,
Switzerland) at the Department of Biochemistry, Aarhus
University Hospital. Also, serum creatinine (SCr), serum
sodium, urinary albumin and sodium were measured as
routine analyses at the Department. AKI was defined
according to the definition proposed by Jetton et Askenazi
based on the neonatal acute kidney injury (AKIN) classifi-
cation [15–17]. AKI Stage 0: no change or rise SCr <
0.3 mg/dl; Stage 1: increase SCr 0.3 mg/dl or increase SCr
150–200% from previous trough value; Stage2: increase
SCr 200–300% from previous trough value; Stage 3: in-
crease SCr 200% from previous trough value or 2.5 mg/dl
or recipient of dialysis [15]. Six stable neonates only
had one SCr measured, this was within normal range
and they were categorized as not having AKI. To
evaluate renal dysfunction we measured urine albu-
min and calculated fractional excretion of sodium
(FENa). Fractional excretion of sodium was calculated
using the following formula: FENa (%) = (UNa/ PNa) *
(SCr/ UCr) * 100, where UNa = urine sodium (mmol/l);
PNa = plasma sodium (mmol/l); SCr serum creatine
(μmol/l); and UCr = urine creatinine (μmol/l).
Statistical analysis
U-NGAL, urine albumin, SCr, and FENa were trans-
formed by the natural logarithm (ln) to normalize the dis-
tribution of residuals. Geometric means were compared
using the Student’s t-test and proportions using Fisher’s
exact test. Univariate and multivariate log-linear regres-
sion was performed in order to examine the association
between U-NGAL and PDA day 3, PDA size, perinatal
characteristics, and sepsis. We consequently exponen-
tiated the differences estimated on the natural log scale to
obtain ratios of the medians. The formula (expbeta -1) *
100% was used to express the percent change. These ratios
are presented as crude and adjusted percent change per
unit of explanatory variable or difference from reference
group with 95% confidence interval (CI). Univariate and
multivariate log-log regression was performed to examine
the association between U-NGAL and parameters of renal
dysfunction. The formula (1.01beta-1)* 100% was used to
express the percent change in U-NGAL per 1% change in
urine albumin, SCr or FENa with 95% CI. Univariate and
multivariate logistic regression was performed to examine
the association between AKI and PDA. Odds ratio (OR)
was presented with 95% CI. Estimates were adjusted for
gestational age as a continuous variable (weeks) and gen-
der and sepsis as dichotomized variables. Robust cluster
standard errors were used in order to take into account
the correlation between twins. Data were analyzed with
STATA special edition version 11 (College Station, Texas,
USA). All tests were two-sided. P-values of less than 0.05
were considered statistically significant.
Results
Patient characteristics
A total of 146 neonates were included in the study
(Fig. 1). A PDA day 3 was found in 67 (46%) neonates
on day 3 and 41 (61%) of neonates with PDA had a
large PDA. Characteristics of the 146 very preterm
neonates in the study are found in Table 1. Neonates
with large and small PDA had comparable character-
istics (data not shown).
U-NGAL in neonates with PDA
U-NGAL levels day 3 in neonates with PDA and no
PDA on day 3 in four gestational age groups are found
in Fig. 2. The highest level of U-NGAL day 3 was found
in neonates with a small PDA compared to neonates
with no PDA or a large PDA day 3 (Table 2). Median U-
NGAL day 3 was 53% higher in neonates with a PDA
compared to neonates without a PDA (Table 3). How-
ever, after adjusting for gender, gestational age, and
sepsis by multivariate linear regression the association
was no longer present. And no association was found
between PDA or PDA size day 3 and U-NGAL.
AKI in neonates with PDA
A total of seven neonates were found to have AKI. AKI
was found more frequently in neonates with PDA com-
pared to neonates with no PDA and especially in neo-
nates with a large PDA compared to no PDA day 3
(Table 2). However, when adjusted for gestational age
no association between PDA day 3 and AKI was
found. The odds of AKI decreased some 40% for every
1 week increase in gestational age at birth (OR = 0.64;
95% CI 0.4–0.96).
Mean SCr, urinary albumin, and FENa are described in
Table 2. No difference in SCr was found between PDA
groups. We found that urine albumin and FENa was
higher in neonates with PDA day 3 compared to neonates
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with no PDA. On regression we found PDA and PDA size
to be associated with urine albumin also when adjusted
for adjusting for gender, gestational age, and sepsis. No as-
sociation between PDA or PDA size and FENa was found
when adjusted for gestational age.
U-NGAL in neonates with AKI
We found no association between U-NGAL measured
day 3 and AKI (Table 3). In 126 neonates we measured
U-NGAL day 6. However, also on day 6 we found no as-
sociation between U-NGAL and AKI. No association be-
tween U-NAGL day 3 and SCr was found. We did find
an association between U-NGAL day 3 and both urine
albumin and FENa also when adjusting for gender, gesta-
tional age, and sepsis.
Discussion
In 146 consecutively examined very preterm neonates,
we found that the mere presence of a PDA and the PDA
size day 3 was not associated with U-NGAL after adjusting
for gestational age and gender. AKI was found more often
in neonates with PDA, but after adjusting for gestational
age there was no association between PDA day 3 and AKI.
We found that neonates with PDA day 3 had higher urine
albumin compared to neonates with no PDA. PDA and
PDA size was associated with urine albumin also when
adjusted for gestational age, gender, and sepsis. U-NGAL
was not associated with AKI, it was however found to be
associated with both urine albumin and FENa.
Tosse et al. found that U-NGAL in neonates with a birth
weight below 1,500 g was higher if a PDA that needed
either medical or surgical intervention was present than in
neonates with no PDA or a PDA with no need for interven-
tion [10]. They diagnosed the PDA by echocardiography on
day 1–3 but the need for medical or surgical intervention
was based on respiratory setback, oliguria or failure to
thrive. Recently PDA diameter has been recognized as an
important marker to evaluate the magnitude and clinical
significance of the PDA [1, 18–20]. We used a PDA diam-
eter above 1.5 mm on day 3 to identify the clinically signifi-
cant PDA as we have previously shown that it is associated
with severe morbidity and mortality [1]. Markers of organ
dysfunction prior to clinical morbidity are needed in order
to evaluate the PDA. The hemodynamic effects of a PDA
may cause renal hypoperfusion and renal ischemia leading
Table 1 Characteristics of 146 very preterm neonates postnatal day 3
no PDA PDA P value
(n = 79) (n = 67)
Gestational age weeks, median (range) 29 (24; 31) 27 (23; 31) <0.01
Birth weight grams, median (range) 1190 (470;2160) 940 (570;1840) <0.05
Singleton, number (%) 59 (75) 32 (48) <0.01
SGA, number (%) 28 (35) 14 (21) 0.07
Sex (female:male) 27:52 28:39 0.39
Apgar score at 1 min, median (IQR) 8 (5;10) 7 (5;8) <0.05
Apgar score at 5 min, median (IQR) 9 (7;10) 10 (9;10) 0.30
Sepsis, number (%) 9 (11) 13 (20) 0.25
Surfactant, number (%) 29 (37) 37 (55) <0.05
PRBC transfusion, number (%) 8 (10) 16 (24) <0.05
Inotropes, number (%) 5 (6) 7 (11) 0.39
Preeclampsia, number (%) 27 (34) 7 (11) <0.01
Antenatal steroids, number (%) 75 (97) 61 (95) 0.66
Cesarean delivery, number (%) 56 (71) 44 (66) 0.59
SGA small-for-gestational-age (birth weight below 3rd percentile for gestational age); Sepsis defined as 7 days of antibiotics initiated before day 3; PRBC packed
red blood cell transfusion within first 3 days of life; Inotropes used within the first 3 days of life
Fig. 2 Urine neutrophil gelatinase-associated lipocalin (U-NGAL) in
146 very preterm neonates with no PDA (white) and PDA (grey)
assessed at postnatal day 3
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to AKI [21, 22]. Also management of the PDA including
Indomethacin, Ibuprofen or fluid restrictions may
alter renal function or cause AKI [23, 24]. Neonates
in this study were not subjected to any of these treat-
ment strategies prior to the first echocardiography
and collection of urine day 3.
In concordance with previous studies we found that
U-NGAL decrease with higher gestational age at birth or
birth weight and also that U-NAGL is higher in girls
than in boys in preterm neonates [8, 9, 25]. Gestational
age could therefore partly explain why Tosse et al. report
higher U-NGAL levels in neonates with PDA needing
intervention compared to neonates with no PDA or a
PDA with no need for intervention. Neonates who
required intervention in the study by Tosse et al. had a
lower gestational age at birth than the neonates with
PDA in our study, whereas the non-intervention group
and the neonates with no PDA had similar gestational
ages as ours. Tosse et al. did not adjust for gestational
age in their analysis. When adjusted for gestational
age and gender we found no association between
PDA and U-NGAL which is in also in agreement with
Laundry et al. [9].
AKI is defined as a sudden decline in kidney function
resulting in derangements in fluid balance, electrolytes,
and waste products. Currently a modified neonatal
Kidney Injury: Improving Global Outcomes (KIDGO)
classification of AKI accepted at the National Institute of
Diabetes and Kidney Disease (NIDDK) workshop 2013 is
used [26]. The applicability of these criteria for AKI in
neonates is problematic because they include SCr and
urinary output. Neonates often have non-oliguric renal
failure [27]. SCr is difficult to interpret in preterm neo-
nates due to incomplete nephrogenesis and the potential
Table 2 U-NGAL, SCr, FENa, urine albumin, and AKI in 146 very preterm neonates postnatal day 3
no PDA PDA small PDA large PDA
n = 79 n = 67 n = 26 n = 41
U-NGAL day 3 (μg/l) 104 (79; 136) 158 (125; 201)* 177 (117; 266)* 148 (110; 200)*
U-NGAL day 6 (μg/l) 87 (63; 118) 139 (103; 190)* 166 (103; 267)* 126 (83; 190)
SCr (μmol/l) 78 (75; 82) 78 (75; 82) 78 (73; 84) 78 (74; 83)
Urinary albumin (mg/l) 29 (24; 36) 62 (51; 77)* 56 (41; 76)* 67 (51; 90)*
FENa (%) 2.6 (2.3; 2.9) 3.6 (3.2; 4.2)* 3.8 (3.0; 4.8)* 3.6 (3.0; 4.2)*
AKI, number (%) 1 (1) 6 (9)* 2 (8) 4 (10)*
NGAL urine neutrophil gelatinase-associated lipocalin, SCr serum creatinine, AKI acute kidney injury, FENa fractional excretion of sodium, PDA diameter <1.5 mm
small PDA, PDA diameter ≥1.5 mm large PDA. Values are geometric mean (95% confidence interval) or number (percentage). *p < 0.05 compared to neonates with
no PDA. U-NGAL day 6 was only measured in 126 neonates
Table 3 Influence of perinatal characteristics, sepsis, renal parameters, AKI, and PDA on U-NGAL in 146 very preterm neonates
Percent change in U-NGAL Day 3
Crude Adjusted GA, gender Adjusted GA, gender, sepsis
Per gestational week −17 (−23; −10)
Girls only −12 (−22; −0.2)
Boys only −20 (−27; −12)
Male gender vs. female −58 (−70; −40)
Sepsis vs. no sepsis 329 240 (103; 466)
Per percent increase SCr 0.4 0.3 (−0.6; 1.2) 0.7 (−0.2; 1.5)
Per percent increase urine albumin 0.6 0.5 (0.3; 0.7) 0.5 (0.3; 0.6)
Per percent increase FENa 0.7 0.5 (0.2; 0.8) 0.3 (0.0; 0.6)
PDA vs. no PDA day 3 53 0.3 (−30; 40) 0.4 (−27; 35)
Small PDA vs. no PDA 70 14 (−27; 76) 0.0 (−32; 47)
Large PDA vs. no PDA 42 −5 (−34; 38) 2.3 (−32; 41)
AKI vs. no AKI −15 −18 (−63; 80) −25 (−63; 52)
AKI vs. no AKI 34a 24 (−60; 295) 19 (−60; 269)
Percent change in U-NGAL (95% CI) concentration by one unit increase in gestational age, by 1% increase in SCr, urinary albumin, and FENa and difference in con-
centration between groups (male vs. female, sepsis vs. no sepsis, PDA vs. no PDA, AKI vs. no AKI). aU-NGAL measured day 6 in 126 neonates all other U-NGAL was
measured day 3
U-NGAL urine neutrophil gelatinase-associated lipocalin, GA gestational age, SCr serum creatinine, FENa fractional excretion of sodium, AKI acute kidney injury, PDA
diameter < 1.5 mm small PDA, PDA diameter ≥ 1.5 mm large PDA
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impact of bilirubin on the measure of SCr. In the first
days of life maternal renal function also plays a signifi-
cant role in the magnitude of newborn SCr due to pla-
cental transfer [27]. Previous studies using a plethora of
AKI definitions have found an association between AKI
or altered renal function and PDA [28, 29]. At the time
our study was designed and performed the modified
neonatal AKIN classification as proposed by Jetton et
Askenazi was used [15]. This definition does not include
urinary output. In a cohort of very preterm neonates
that all had an echocardiography day 3 to diagnose PDA
we found that seven neonates (5%) had AKI within the
first week of life. We found that AKI was associated with
gestational age, but not PDA.
The renal function in premature neonates is affected by
both immaturity with a decreased ability to reabsorb elec-
trolytes and protein and to concentrate urine and by an
increased risk of injury during the early postnatal period
due to multifactorial morbidity, medication, umbilical
artery catheter, and hemodynamic instability [26, 30, 31].
Urinary albumin is inversely related to gestational age,
which may reflect tubular immaturity, tubular damage
and glomerular dysfunction [12, 30, 32]. We found urine
albumin to be associated with PDA and PDA size also
when adjusted for gestational age, gender, and sepsis. A
recent study found urinary albumin to be increased in
preterm neonates treated with indomethacin compared to
neonates that did not receive indomethacin. No informa-
tion on the PDA was given in that study [33]. Urinary
albumin has been found to be increased in preterm neo-
nates with asphyxia and respiratory distress and has been
suggested as a possible biomarker of AKI in newborns
[32, 34] and preterm neonates [35]. In concordance with
our findings FENa is known to be very high in preterm
neonates and inversely related to gestational age [36].
Several mechanisms may cause this including immature
tubular function, low density of sodium transporters in
the tubular epithelium, and a physiological response to re-
distribution of extracellular fluids. After adjusting for ges-
tational age, gender and sepsis we found no association
between FENa and PDA.
Due to the difficulties in diagnosing AKI in preterm neo-
nates, studies have investigated different biomarkers in
order to allow also for earlier identification of neonates with
AKI [26, 37]. An association between AKI and U-NGAL
has been described in preterm neonates [8, 9, 38–40]. The
definition of AKI differed in these studies, but they all
included SCr. We found that U-NGAL was not an early
marker of AKI in our population as we found no associ-
ation between U-NGAL day 3 and AKI. Furthermore U-
NGAL day 6 was not associated with AKI. In concordance
with our findings Gubhaju et al. found no association be-
tween AKI and U-NGAL [30]. Gubhaju et al. recently de-
scribed an association between U-NGAL and urine total
protein, but contrary to us they did not find a positive asso-
ciation between U-NGAL and urine albumin [30]. In-
creased U-NGAL in extremely preterm neonates may be
associated with infection, inflammation or indicate differen-
tiation and growth of renal epithelium caused by immature
nephrons stimulating glomerulogenesis [38, 41, 42]. We
found U-NGAL to be associated with sepsis in very pre-
term neonates.
In our analyses we adjusted for gestational age, gender,
and sepsis as previous studies found that they may influ-
ence U-NGAL levels. We included a total of 146 very
preterm neonates in this study. Despite this being the
largest cohort evaluating U-NGAL in preterm neonates,
a larger cohort would be needed to allow control for
more covariates and to facilitate subanalyses by
gestational-age. Day-to-day variation has been described
in both U-NGAL and SCr. Unfortunately; we could not
collect all samples at the exact same time after birth.
However, the variation in time of collection was similar
in neonates with and without PDA. Renal complications
in neonates with PDA may be due to hemodynamic ef-
fects of the PDA or to treatment strategies used. We
were able to measure U-NGAL (day 3) before Ibuprofen
was administered. However, all but one of the six neo-
nates with PDA that were diagnosed with AKI received
Ibuprofen in the interval between the two measurements
of SCr used to define AKI.
Conclusion
In this cohort of 146 very preterm neonates we found
no association between U-NGAL and PDA day 3 after
adjusting for gestational age and gender. We found that
PDA day 3 was associated with urine albumin; however
PDA was not associated with AKI and FENa when
adjusted for gestational age and gender. No association
between U-NGAL and AKI was found. U-NGAL day 3
was associated with both urine albumin and FENa. Non-
renal disease may constitute important confounders in
the interpretation of NGAL and highlight the need for
an enhanced understanding of the interactions between
cardiovascular function, inflammation, AKI, and the risk
of adverse outcome. At the present time U-NGAL is not
useful as a diagnostic marker to identity very preterm
neonates with a PDA causing hemodynamic changes
resulting in renal morbidity within the first week of life.
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